Rheumatoid Arthritis Industry 2018 – Company Profile, SWOT Analysis, Access Potential, Size, Share, Growth, Trends and Forecast

Apr 10, 2018

WiseGuyReports.com adds “Rheumatoid Arthritis Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting ”reports to its database.

Pune, India - April 10, 2018 /MarketersMedia/ —

Rheumatoid Arthritis Market:

Executive Summary

Adroit Healthcare Services Rheumatoid Arthritis - Competitive Landscape and Market, Market Access Potential, Pricing & Pipeline Analysis, 2018' provide the comprehensive research on the competitive landscape and therapies indicated for rheumatoid arthritis.

The report is built with the in-depth secondary research, understanding the market access aspects across the different countries. The main objective of this report is to provide a comprehensive secondary research and market analysis of different therapies indicated for rheumatoid arthritis including the market access and reimbursement challenges across EU5 and US.

The report includes in depth sales reports of different class of therapies, detailed mechanism of action, comprehensive clinical trial data, time line of important events, pricing and market access across the significant markets (EU3+US). This report also includes the pipeline analysis of filed, phase 3, phase 2, phase 1, preclinical products across the different classes.

This report also provides comprehensive research on the companies that are working on different class of drugs for rheumatoid arthritis including the deals and acquisitions (collaborations and merges).

Companies Mentioned

Merck, Janssen Biologics B.V., Pfizer Limited, Amgen, Novartis, GSK, Celgene, Eli Lilly, Abbvie, Sanofi

Request Sample Report @ https://www.wiseguyreports.com/sample-request/3096398-rheumatoid-arthritis-competitive-landscape-and-market-market-access

Table of Content

Disease Landscape

Etiology and Pathophysiology
Disease Overview
Key Pathways and Drug Targets
Market Overview

Therapeutic assessment by drug class

TNF-Alpha Inhibitors
B-Cell-Targeted Therapies
IL-6 Inhibitors
JAK Inhibitors
RANKL Inhibitors
Adenosine Receptor Agonists
Market Drivers and Constraints

Current Treatment Overview

Key Findings

Key Current Therapies

Humira & Biosimilars
Remicade & Biosimilars
Enbrel & Biosimilars
Simponi
Cimzia
Orencia
Olumiant
Rituxan/MabThera
Kineret
Kevzara

Biosimilars Drug profiling

GP2017/Sandoz
BI695501/Boehringer Ingelheim
PF-06410293/Pfizer
FKB327/Fujifilm Kyowa Kirin Biologics
MYL-1401A/Biocon/Mylan
CHS-1420/Coherus
M923/Momenta
ONS-3010/Oncobiologics/ Viropro
MSB11022/Fresenius
Unmet Need Overview

Pipeline Analysis

Late Stage Pipeline Analysis
Mid Stage Pipeline Analysis
Early Stage Pipeline Analysis
Discontinued Products
Access & Reimbursement Overview

United States
EU5
Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/3096398-rheumatoid-arthritis-competitive-landscape-and-market-market-access

Contact Info:
Name: NORAH TRENT
Email: [email protected]
Organization: Wise Guy Research Consultants Pvt Ltd
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349 (US); +44 208 133 9349 (UK)

Source URL: https://marketersmedia.com/rheumatoid-arthritis-industry-2018-company-profile-swot-analysis-access-potential-size-share-growth-trends-and-forecast/328447

For more information, please visit https://www.wiseguyreports.com/reports/3096398-rheumatoid-arthritis-competitive-landscape-and-market-market-access

Source: MarketersMedia

Release ID: 328447

More News

YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

Copyright © 2015 - 2026 The Financial Capital.

All Rights Reserved.

Subscribe Now!

About Us

The Financial Capital is your independent source for finance information and advice. We provide insights and offer advice from financial experts so you can make the best decisions.